Procter & Gamble Health Limited (PGHL) announced its audited financial results for the quarter and financial year ended March 31, 2026, in a Board Meeting held on May 26, 2026. The company reported a Revenue from Operations of 37,045 lakhs for the quarter ended March 31, 2026, compared to 37,386 lakhs in the preceding quarter (December 31, 2025) and 31,099 lakhs in the corresponding quarter of the previous year (March 31, 2025). The Net Profit for the quarter ended March 31, 2026, stood at 9,460 lakhs, reflecting a growth compared to the profit of 7,759 lakhs in the preceding quarter and 6,118 lakhs in the corresponding quarter last year. Additionally, the Board recommended a final dividend of Rs. 45 per equity share for the financial year ended March 31, 2026.

Procter & Gamble Health Limited is one of India’s largest Vitamins, Minerals, and Supplements (VMS) companies, manufacturing and marketing over-the-counter products focused on a healthy lifestyle and improved quality of life. The company is known for its strong portfolio of brands backed by science and trusted by doctors, pharmacists, and consumers. It operates a manufacturing site at Usgaon, Goa, which is a major facility for producing pharmaceutical and chemical products, including vitamins and sterile formulations. The company, formerly part of Merck, became an affiliate of The Procter & Gamble Company in 2018 following the acquisition of Merck’s Consumer Health business.